Cingulate Announces Closing of $4.0 Million Public Offering
September 13, 2023 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023 09:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 11, 2023 06:00 ET
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
September 08, 2023 16:31 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
The Southport School Announces Kate Haft as Director of Development
August 24, 2023 11:10 ET
|
The Southport School Inc
SOUTHPORT, Conn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- The Southport School, an independent day school for cerebrodiverse children in grades 2-8 with language-based learning differences such as...
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023 16:15 ET
|
Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...
Attention Deficit Hyperactivity Disorder Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight
July 17, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 17, 2023 (GLOBE NEWSWIRE) -- Attention Deficit Hyperactivity Disorder Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight ...
NeuroSigma Establishes Singapore Subsidiary
July 12, 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...